NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

NCT02791230

CompletedPhase 3

Sponsor: Pfizer

Conditions: Transthyretin (TTR) Amyloid Cardiomyopathy

Interventions: Tafamidis

Countries: United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, France

Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

Cohort A: Completion of 30 months of study treatment on Pfizer Protocol B3461028

Cohort B: Patients in specific countries diagnosed with ATTR-CM who did not previously participate in Pfizer Study B3461028

Exclusion Criteria:

-Liver and/or heart transplant, or implanted cardiac mechanical assist device

Locations (80)

Birmingham, Alabama, United States
Birmingham, Alabama, United States
Birmingham, Alabama, United States
Beverly Hills, California, United States
Beverly Hills, California, United States
La Jolla, California, United States
La Jolla, California, United States
Los Angeles, California, United States
San Diego, California, United States
San Diego, California, United States
San Francisco, California, United States
San Francisco, California, United States
San Francisco, California, United States
Stanford, California, United States
Deerfield Beach, Florida, United States
Miami, Florida, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Oak Lawn, Illinois, United States
Baltimore, Maryland, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Ann Arbor, Michigan, United States
Rochester, Minnesota, United States
Rochester, Minnesota, United States
Newark, New Jersey, United States
New York, New York, United States
New York, New York, United States
+ 50 more on CT.gov